Reconciliation in Place Names Act This bill directs the Department of the Interior to establish the Advisory Committee on Reconciliation in Place Names to advise the Board on Geographic Names with regard to renaming geographic features with offensive place names. The board shall rename a geographic feature with an offensive name in accordance with a recommendation of the committee unless the board determines that (1) there is a compelling reason and substantial public interest in rejecting the recommendation, or (2) approving the recommendation would violate federal law. The board shall accept or reject a recommendation within three years of receiving the recommendation.
January 8th National Memorial Act This bill directs the Department of the Interior to establish the January 8th National Memorial in Tucson, Arizona, as an affiliated area of the National Park System in commemoration of the shooting of Congresswoman Gabrielle Giffords and 18 others in Tucson on January 8, 2011. The January 8th Memorial Foundation shall transfer to Pima County, Arizona, amounts equal to final funding pledges, in addition to the amounts that the foundation has raised and transferred to the county for the construction of the memorial. The memorial shall be constructed on property owned by Pima County. The bill makes the county responsible for the management of the construction contract for the memorial through the use of funds provided by the foundation. The foundation shall cease operations after (1) final funding pledge amounts have been paid to Pima County, and (2) construction of the memorial has been completed. Pima County shall (1) be the memorial's management entity, and (2) be responsible for the construction and operation of the memorial. Interior shall develop a general management plan for the memorial.
This resolution expresses support for the designation of National Vitiligo Awareness Day. (Vitiligo is a chronic condition that results in the loss of pigment in patches on the skin, hair, eyes, and inside of the mouth; the condition may lead to discomfort, itching, and pain.)
Consider Teachers Act of 2021 This bill revises the service obligation verification process for the Teacher Education Assistance for College and Higher Education (TEACH) grant program. The TEACH program awards grants to postsecondary students who commit to teaching for four years in high-need subjects in low-income schools. In addition, the bill establishes certain program flexibilities with respect to the service obligations of teachers affected by the COVID-19 pandemic. Specifically, the bill provides a process for the Department of Education (ED) to reconsider and reverse the conversion of a TEACH grant to a loan. Under current program terms, TEACH grants are converted into loan obligations if service requirements are not met. In addition, the bill directs ED to notify TEACH grant recipients of the requirements for submitting employment certifications. ED must also provide an alternative to certification. ED must maintain and annually update a list of qualifying schools and high-need fields. The bill also provides certain program flexibilities with respect to the service obligations of teachers affected by the COVID-19 pandemic. In particular, the bill (1) extends the service obligation window for TEACH grants, and (2) requires ED to consider teaching service that is interrupted as a result of a qualifying emergency as full-time service for purposes of Federal Perkins Loans.
Fair Drug Prices for Kids Act This bill allows states to apply the requirements of the Medicaid Drug Rebate Program to covered outpatient drugs under the Children's Health Insurance Program (CHIP).
Finding Orphan-disease Remedies With Antifungal Research and Development Act of 2021 or the FORWARD Act of 2021 This bill establishes programs to support research on endemic fungal diseases and the development of antifungal drugs, with a particular focus on Valley Fever. Endemic fungal diseases are fungal infections that tend to occur in specific geographic areas and affect older adults and other at-risk populations. Specifically, the bill establishes the Endemic Fungal Disease Working Group to review, coordinate, and make recommendations about the Department of Health and Human Services' efforts to address endemic fungal diseases. The working group is comprised of experts from both relevant federal agencies and the private sector. In addition, the National Institutes of Health must continue its support for research on endemic fungal diseases. Furthermore, the Food and Drug Administration must issue guidance for entities seeking approval for therapies, diagnostics, and vaccines to prevent and treat Valley Fever. Additionally, the bill provides for the use of priority reviews and other fast-track procedures to incentivize and expedite development and approval of these medical products. The bill also requires the Biomedical Advanced Research and Development Authority to implement the Combating Antimicrobial Resistance Biopharmaceutical Accelerator Program to reduce and prevent antimicrobial resistance.
Urban Waters Federal Partnership Act of 2021 This bill provides statutory authority for the Urban Waters Federal Partnership Program. Under the program, the Environmental Protection Agency and other specified agencies must reconnect urban communities, particularly urban communities that are overburdened or economically distressed, with their waterways by improving coordination among federal agencies.
This resolution provides for consideration of H.R. 1259 (requiring the Department of Homeland Security to implement the Migrant Protection Protocols).
Cosmetic Supply Chain Transparency Act of 2021 This bill requires the Food and Drug Administration (FDA) to maintain a list of certain nonfunctional constituents in cosmetics that are harmful to human health or the environment, authorizes the FDA to request from a brand owner (i.e., the entity bringing a cosmetic to market) certain information about a cosmetic's ingredients, and addresses related issues. For each listed nonfunctional constituent, the list must identify the ingredient or cosmetic (or category of ingredient or cosmetic) in which the constituent is known or reasonably expected to be present. The FDA must also (1) establish procedures for petitions to add substances to the list, (2) issue guidance for industry related to testing and detecting such nonfunctional constituents, and (3) establish a committee to provide advice on creating the list and developing the required industry guidance. Within a year of a nonfunctional constituent being added to the list, a supplier of an ingredient or cosmetic must test for that constituent and provide a brand owner the results and other information before selling the ingredient or cosmetic to the brand owner. A supplier of an ingredient or cosmetic must provide additional information about the item upon a brand owner's request. Brand owners must maintain records with information about the suppliers of ingredients and raw materials used in their cosmetics and provide such information to the FDA upon request. The bill also imposes civil penalties for brand owners and suppliers that violate this bill's provisions.
HR 5537, the Toxic-Free Beauty Act of 2021, bans specific chemicals in cosmetics under federal law. It prohibits the use of substances like certain PFAS (water-repellent chemicals), phthalates (e.g., dibutyl phthalate), formaldehyde, mercury, and specific parabens in cosmetic products. The ban directly affects cosmetic manufacturers, requiring them to reformulate products, and benefits consumers by removing these chemicals from beauty items. The law takes effect on January 1, 2025, with the ban applying to products bearing or containing the listed substances.
Cosmetic Fragrance and Flavor Ingredient Right to Know Act of 2021 This bill imposes disclosure and labeling requirements on cosmetics products that contain certain ingredients. A cosmetics product that fails to meet such requirements may not be sold. Within two years of this bill's enactment, a cosmetics product's labeling or packaging must indicate the use of any ingredient that (1) is identified on specified lists of harmful or potentially harmful chemicals, such as chemicals identified as carcinogenic to humans by the Environmental Protection Agency or toxic air contaminants under California regulations; or (2) must be disclosed under certain European Union laws and is present in a product above specified concentrations. The Food and Drug Administration must publish and periodically update on its website a list of the ingredients subject to this requirement. Within one year of this bill's enactment, a brand owner (i.e., the entity bringing a cosmetics product to market) must disclose certain information on its website if a cosmetics product contains any fragrance or flavor ingredient that is (1) present in the product above a certain concentration, or (2) subject to this bill's labeling or packaging requirement. The website must disclose the use of the ingredient in question and other information, such as the ingredient's functional purpose. The use of an ingredient subject to this bill's requirements shall not be treated as a confidential trade secret, but the concentration of such an ingredient shall be treated as confidential commercial information.
Cosmetic Safety for Communities of Color and Professional Salon Workers Act of 2021 This bill imposes labeling requirements on cosmetics intended for professional use, requires research on health issues relating to cosmetics, and addresses related issues. The Food and Drug Administration (FDA) must require (1) the labeling for cosmetics intended for professional use to include the name of each ingredient in descending order of predominance; and (2) the manufacturer, distributor, or seller of such a cosmetic to provide this information on its website. The Occupational Safety and Health Administration must issue a standard requiring each manufacturer or importer selling a cosmetic intended for professional use to (1) obtain or develop a safety data sheet for the cosmetic in various languages; and (2) make the data sheet available to relevant distributors and employers, such as hair salon owners. The standard must also require employers to make the data sheet available to employees exposed to the product and provide to employees versions of the sheet in languages other than English upon request. The FDA must conduct (or award grants for) research into chemicals linked to adverse health effects and most commonly found in cosmetics that are (1) marketed to women and girls of color; or (2) used by professional nail, hair, and beauty salon workers. The FDA must also award grants to support research focused on designing safer cosmetic chemicals, such as those with no inherent toxicity. The FDA must take actions to ensure that cosmetics marketed to women and girls of color are in full compliance with FDA requirements.
